Ian Quigley, Leash Bio CEO
August 15, 2024 07:00 AM EDTUpdated 08:09 AM
AI

In a re­al­i­ty check for the field, AI un­der­whelms in Leash Bio's bind­ing con­test: 'No one did well'

Andrew Dunn

Senior Biopharma Correspondent

Ar­ti­fi­cial in­tel­li­gence mod­els may be do­ing a lot more mem­o­riz­ing and a lot less rea­son­ing when it comes to pre­dict­ing bi­ol­o­gy,

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times